Kornimate/medical-research-clean huggingface dataset:
effects of compelled body weight shift technique for rehabilitation of individuals with chronic stroke

Conditions: Chronic Stroke

Summary: stroke is one of the major cause of lifelong disability if not treated on time, the investigator's technique knows as compelled body weight shift technique (cbws) was utilized and administered to chronic stroke population and results were figured out using gait parameters and tinetti poma scale.

total 28 sample size out of which 27 were divided into control and experimental group. inclusion criteria was unilateral chronic stroke with asymmetrical stance, patients with score of 3,4 and 5 will be included according to fas (functional ambulation scale), ability to understand and follow instructions, both male and female, any type of stroke, and age 40-60. written and informed consent was obtained from participants of study. six weeks of exercise training was combined with compelled body weight shift technique via shoe lift of 0.6 cm thickness for experimental group and for control group training was performed without shoe lift.

Eligibility criteria:
inclusion criteria: * unilateral chronic stroke with asymmetrical stance * patients with score of 3,4 and 5 were included according to functional ambulation scale(59) * ability to understand and follow instruction * both male and female. * any type of stroke. * age 40-60. exclusion criteria: * • serious or unstable medical, condition of patient. * history of other neurological diseases (i.e. parkinson's disease, multiple sclerosis), * contractures or any deformity. * leg length discrepancy

Keywords: compelled body shift technique stroke tinetti performance oriented mobility assessment
covid 19 serology in pulmonologists

Conditions: Covid 19

Summary: respiratory physicians are highly exposed workers to covid-19 as they perform spirometry, endoscopy, and manage covid-19 in first line for most of them. moreover, none reported to have apply increased levels of protection for performing these acts in the most active period of viral circulation, until the lockdown. whether they were most frequently immunized against sars-cov-2 at the end of the first wave than the general population is of utmost importance individually but also worldwide


Eligibility criteria:
inclusion criteria: * pulmonologists of languedoc roussillon * actively working * registered exclusion criteria: * refusal to participate

Keywords: covid 19 serology
a small dose of naloxone,minimize intrathecal morphine side effects

Conditions: Post-Op Complication

Summary: i.v naloxone decreases incidence and severity of the common morphine side effects (pruritis, nausea/emesis, constipation, urinary retention, respiratory depression and undesirable sedation) so using it as additive to intrathecal morphine in patients undergoing anal surgeries under spinal anesthesia may be beneficail

bupivacaine hydrochloride is a commonly used local anesthetic in spinal anesthesia, however, the duration of spinal analgesia by bupivacaine is limited to about 75-150 minutes, therefore, various additives have been used along with bupivacaine for the prolongation of its effect, to improve the quality of analgesia, and to minimize the requirement for postoperative analgesics . opioids may be added to local anesthetic solutions to enhance surgical anesthesia and provide postoperative analgesia . this effect is mediated at the dorsal horn of the spinal cord, where opioids mimic the effect of endogenous enkephalins. the use of intrathecal (it) morphine (0.1 to 0.5 mg) can provide effective control of postoperative pain for roughly 24 hours . however, the use of it morphine may result in serious side effects e.g. pruritus 53%, nausea and vomiting 43%.urinary retention 43% and delayed respiratory depression . these side effects may lead to patient discomfort and prolonged hospital stay thus limiting the usefulness of it morphine. naloxone has an extremely high affinity for μ-opioid receptors in the central nervous system (cns). naloxone is a μ-opioid receptor (mor) competitive antagonist, and its rapid blockade of those receptors often produces rapid onset of withdrawal symptoms. naloxone also has an antagonist action, though with a lower affinity, at κ- (kor) and δ-opioid receptors (dor). unlike other opioid receptor antagonists, naloxone is essentially a pure antagonist with no agonist properties. i.v naloxone decreases incidence and severity of the common morphine side effects (pruritis, nausea/emesis, constipation, urinary retention, respiratory depression and undesirable sedation) the addition of naloxone to morphine decreases the opioid related side effects without affection of postoperative analgesia. this combination can be used for the treatment of severe refractory chronic low back pain.

Eligibility criteria:
inclusion criteria: * asa physical status i - ii * undergoing anal surgery with spinal anesthesia exclusion criteria: * renal ,hepatic and cardiac patients -infection at the site of injection.- * coagulopathy or other bleeding diathesis. -preexisting neurologic deficits.- * history of hypersensitivity to any of the given the drugs. * inability to communicate with the investigator and the hospital staff. * history of chronic opioid use.
effects of hypothermia on delayed neurocognitive recovery (dnr): an observational trial among patients undergoing cardiac-surgery

Conditions: Cognitive Dysfunction; Emergence Delirium; Hypothermia

Summary: post-operative cognitive dysfunction is a common disease in patient undergoing general anaesthesia, especially in older patients. no correlations have been yet studied between intraoperative hypothermia and incidence of delayed neurocognitive recovery. investigators are going to estimate the relative risk of hypothermia and emergence of post-operative cognitive dysfunction in cardiac-surgery patients.


Eligibility criteria:
inclusion criteria: * adults patients undergoing cardiac - surgery intervention with extracorporeal circulation exclusion criteria: * neurological disease before surgery * sedation in cardiac-surgery intensive unit \> 6 hours * cerebral regional oxygen saturation \<20% baseline during surgery
the turkish version of the simple physical activity questionnaire (simpaq)

Conditions: Psychiatric Disorder

Summary: the simple physical activity questionnaire (simpaq) was originally developed in english to assess physical activity level particularly people with mental illnesses. the purpose of this study was to translate and cross-culturally adapt the simpaq into turkish and investigate its psychometric properties.

the simple physical activity questionnaire (simpaq) was originally developed in english to assess physical activity level particularly people with mental illnesses. the purpose of this study was to translate and cross-culturally adapt the simpaq into turkish and investigate its psychometric properties. eighty individuals with mental illnesses (major depression, bipolar disorder, anxiety disorder, schizophrenia, alcohol and substance addiction) will include. for cross-cultural adaptation and validation procedure, developers' manual in the official site will be followed (http://www.simpaq.org/). within a 5-to-7-day period after the first assessment, the participants completed the turkish version of the simpaq to evaluate test-retest reliability. cronbach's alpha (α) was used to assess internal consistency. the correlations with the turkish version of the international physical activity-short form (ipaq-sf) and brief psychiatric rating scale (bprs) and turkish version of the dsm-5 self-rated level 1 cross-cutting symptom scale-adult version (dsm xc) will determine to check the validity.

Eligibility criteria:
inclusion criteria: aged between 18 and 60 years being a volunteer to participate being an outpatient or inpatient at the place of the study being diagnosed with major depression, bipolar disorder, anxiety disorder, schizophrenia, alcohol and substance addiction according to dsm-5 or icd. exclusion criteria: having cognitive impairment having disabilities in understanding, speaking and reading turkish having vision and / or hearing problems

Keywords: physical activity measurement assessment sedentary behaviour mental illness
efficacy study of glyc-101 to evaluate outcomes after post-laser ablation

Conditions: Wounds

Summary: study is intended to evaluate safety and efficacy parameters in patients treated with glyc-101 gel or placebo after laser ablation.

the proposed pilot-study will document feasibility, safety and efficacy of topically applied glucoprime gel (glyc-101 gel 1.0 %) in promoting wound healing in healthy volunteer subjects undergoing retro-auricular carbon dioxide laser skin resurfacing (co2 lsr). the study will observe the effects of the topical agent over the course of 1 month following the treatment. as a preparation for study glyc-101-1b (double-blind, randomized, placebo-controlled phase 2 pilot study to investigate the safety and efficacy of 1.0 % topically applied glyc 101 compared to placebo, in patients undergoing carbon dioxide laser skin resurfacing).

Eligibility criteria:
inclusion criteria: subjects meeting all of the following criteria will be considered for admission to the study: * patients giving informed consent for retro-auricular laser ablation between 25 and 55 years old. * retro-auricular area is free of any irritation, scars or dermatologic conditions which might interfere with the study. * willing and able to participate in the study and follow all study directions. * able to read, understand and sign the consent form. exclusion criteria: * pregnant, nursing, or planning a pregnancy during the course of the study, as determined by the interview and a urine pregnancy test. * systemic or cutaneous disease that may interfere with the study results. * presence of irritation or dermatologic skin conditions in the retro-auricular area. * known allergies to materials within the test formulations. * systemic or cutaneous therapy with medication that impacts wound healing (steroids, immune modulators, immune suppressants).

Keywords: burn wounds wound healing
prescription opioid misuse assessment

Conditions: Chronic Pain

Summary: chronic pain is a worldwide health problem due to its high prevalence and its difficult management with a significant impact on quality of life. pain and addiction co-occur frequently. indeed, the prevalence of addiction in patients with chronic non-cancer pain may affect from 0% to 50% of patients (højsted et al 2010). this large variability in the estimation of addiction prevalence in chronic non-cancer pain patients is at least partly due to a lack of standardization of the selected patients from the clinical or therapeutic point of view and the lack of consensus in the use of a specific evaluation tool or gold standard. indeed, several tools are currently available at the international level with varying efficiencies and precisions (chou et al 2009, turk, swanson, and gatchel 2008, højsted and sjøgren 2007). in france, no data are available on the prevalence of analgesic opioid misuse in chronic non-cancer pain patients, due to the lack clinical studies and validated tools in french.

this is an observational study . each addictovigilance centre will contact pain clinics in order to enroll patients meeting the inclusion criteria. the questionnaires will be prepared and sent to the participating centres by the coordinating centre (clermont-ferrand). participation in the study will be systematically proposed by the physician during the study inclusion period (3 months). patients meeting all inclusion criteria will be enrolled after receiving oral information about the study. this questionnaire can be semi-directed (doctor / nurse / cra) and will be carried out during a consultation as part of their usual care. answering the questionnaire should take no more than 10 minutes. no additional diagnostic or monitoring procedures will be applied to patients.

Eligibility criteria:
inclusion criteria: * patients (male or female) ≥ 18 years old * patients with chronic non-cancer pain for at least 6 months * patients treated with analgesic opioids for at least 3 months exclusion criteria: * patients (male or female) \< 18 years old * patients with chronic pain for less than 6 months * patients with cancer pain * patients treated with analgesic opioids for less than 3 months

Keywords: analgesic opioids misuse use disorder pain
evaluation of different methods of ultrasound image analysis for real-time monitoring of hifu prostate cancer treatment

Conditions: Prostatic Neoplasms

Summary: the elasto-us study is a single center feasibility study to evaluate 3 methods of analyzing real-time ultrasound images acquired during high intensity focused ultrasound (hifu) treatment in patients with localized prostate cancer. real-time ultrasound acquisitions will be programmed at specific times and recorded during hifu treatment. at the end of the treatment, these recordings will be exported in an anonymized way and analyzed according to the 3 different methods. a multiparametric-mri will be performed in addition to the usual practice within 5 days after the treatment in order to control the area necroticised by the treatment. the mp-mri will be the reference method against which the results obtained by the 3 methods of ultrasound image analysis will be compared. techniques capable of providing safe and robust information on the progress of hifu-generated necrosis would greatly limit the risks of overtreatment that can lead to side effects such as urinary incontinence as well as the risks of under treatment that can lead to cancer recurrence.


Eligibility criteria:
inclusion criteria: * patient who has been clearly informed of the study and has agreed, with sufficient time for reflection, to participate by signing the study informed consent form. * male aged ≥ 50 years, * psa ≤ 15 ng/ml * diagnosis of localized prostate cancer (stage t1 or t2) with a gleason score of ≤ 7 * focal, hemiablation or ablation hifu treatment validated in multidisciplinary concerted meeting * patient enrolled in medicare or equivalent plan. * interpretable preoperative multiparametric mri performed within 180 days prior to surgery exclusion criteria: * an asa score \>3 * brachytherapy for prostate cancer * person of full age protected by law (person under guardianship or curatorship). * contraindication to hifu treatment as defined in the focal one instructions for use : - multiple intraprostatic calcifications inducing, on ultrasound, a shadow cone in the prostate preventing the penetration of ultrasound and therefore the realization of the treatment. * presence of permanent radioactive implants in the rectal wall. * presence of an implant (stent, catheter) located less than 1 cm from the treatment area. * fistula of the urinary tract or rectum. * anal or rectal fibrosis, anal or rectal stenosis or other abnormalities making insertion of the focal one® catheter difficult. * anatomical abnormality of the rectum or rectal mucosa. * patient with an artificial sphincter, penile prosthesis or intraprostatic implant, such as a stent. * history of inflammatory bowel disease. * current urogenital infection (infection should be treated prior to hifu treatment). * patient allergic to latex with known severe reactionscounter-indications to anesthesia

Keywords: prostatic neoplasms hifu focal one prostate cancer focal treatment total ablation hemi ablation
a study of the safety and how the body affects a drug (cnto 1959) in healthy volunteers and in patients with psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to evaluate the safety and how the body affects a drug (cnto 1959) in healthy volunteers and in patients with psoriasis.

cnto 1959 is an experimental drug. in this study, cnto 1959 will be tested to see if it may be useful in treating psoriasis. this disease causes inflammation of skin and nails. this is a randomized (study drug assigned by chance), double-blind (neither physician nor patient knows the name of the assigned drug), placebo-controlled study of the experimental drug cnto 1959 in both healthy patients as well as patients with psoriasis. this study will compare the effects (both good and bad) of cnto 1959 to those of placebo. the purpose of this study is to evaluate the safety and potential side effects of cnto 1959 given to healthy volunteers and patients with moderate to severe psoriasis. in addition, the investigators will measure how much study drug is in the blood following a dose of cnto 1959, and determine if the body makes antibodies to it. (an antibody is a protein made by the body in response to a foreign substance). safety assessments will be performed throughout the study and include obtaining and evaluating laboratory tests, vital signs (e.g., blood pressure), and the occurrence and severity of adverse events. this is the first time that cnto 1959 will be studied in humans. there will be 2 parts to this study. the first part of this study will involve healthy volunteers, and the second part of the study will involve patients with psoriasis. about 47 healthy volunteers and 24 patients with moderate to severe psoriasis will take part in the study. enrollment for the healthy volunteer part is closed as of 23sep09. cnto 1959 will be administered as either an intravenous (iv) infusion or subcutaneous (sc) injection. duration of participation may be up to 28 weeks.

Eligibility criteria:
inclusion criteria: * healthy male or female with no clinically significant abnormalities and have a body weight of 50 to 100 kg (enrollment of healthy volunteers closed on 23sep09) * patients with moderate to severe psoriasis and have a body weight not greater than 120 kg. exclusion criteria: * current or a history of any clinically significant medical illness or medical disorders the investigator considers should exclude the patient, including (but not limited to) cardiovascular disease, neuromuscular, hematological disease, respiratory disease, hepatic or gi disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease * known or recent history of alcohol or drug abuse * major or traumatic surgery within 12 weeks of screening * donated blood greater than 500 ml within 56 days of screening * pregnant or nursing * have recently received phototherapy or any systemic medications/treatments that could affect psoriasis

Keywords: cnto 1959 healthy volunteers psoriasis
androcur effects on quality of life

Conditions: Prostate Cancer

Summary: androcur is an antiandrogenic drug, which blocks the action of male sex hormones. androcur is used for treatment of advanced prostate cancer. this study investigates the effect of androcur on quality of life of prostate cancer patients who are taking the drug for 12 months


Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma of the prostate * inoperable prostate tumor or progradiated after surgery/ irradiation therapy * locally advanced tumor or distant metastases is present exclusion criteria: * patient not fulfil the recruitment criteria * liver disease; dubin-johnson syndrome; rotor syndrome; previous or existing liver tumours (in carcinoma of the prostate only if these are not due to metastases); wasting diseases (with the exception of carcinoma of the prostate); depression; previous or existing thromboembolic processes; diabetes with vascular changes; sickle-cell anaemia. * as regards patients with prostatic carcinoma who have a history of thromboembolic processes and/or an existing sickle-cell anaemia, or diabetes with vascular changes, the risk:benefit ratio must be considered carefully in each individual case before the use of androcur
validation of a spasticity measurement tool

Conditions: Stroke

Summary: the objective of this project is to investigate the validity of a handheld spasticity measurement tool against standard clinical measurements of spasticity. we propose the testing apparatus will accurately provide an equivalent clinical measure of spasticity while also providing a more precise estimation of spastic response in persons with stroke.

an ongoing conversation amongst clinicians exists on how to properly define, measure, and manage spasticity. the standard measurement tools are the modified ashworth scale (mas) and the tardieu scale, although both of these lack reliability and specificity, causing variability between clinicians and a lack of accurate spasticity measurement. in addition, some have concerns about whether the mas measures true spasticity at all. due to this lack of trust in these scales, clinicians often use them as a communication tool to identify the presence of spasticity, rather than as reliable quantifiable outcome measurements. the mas and tardieu function mainly on the principal of catch, a limb is moved slowly by a clinician through the available range of motion, and then quickly. hyperactive muscles are sensitive to velocity dependent stretch and will activate a reflex if quickly perturbed. in both the mas and tardieu, the catch location is noted and translated into a score. in mas the catch location is only noted in three distinct ranges; with the tardieu scale the catch angle is remembered by the clinician and recorded after the movement with a standard goniometer. here we will test a new handheld spasticity measurement tool mitss (modified intelligent tardieu scale for spasticity), which is essentially a 3-dof digital goniometer, to quantify the catch angle as well as general forces at the joint.

Eligibility criteria:
inclusion criteria: * age 18-75 * able to provide informed consent * history of unilateral stroke exclusion criteria: * orthopedic injuries or surgeries that would impact arm function

Keywords: spasticity hyperreflexia clonus hypertonia
glitazone treatment for coronavirus hypoxia, a safety and tolerability open label with matching cohort pilot study

Conditions: Coronavirus Infection; Diabetes

Summary: pioglitazone is an approved anti-hyperglycemic medication and is thought to have anti-inflammatory properties. this study seeks to gather safety and tolerability data related to pioglitazone when given to patients who require hospital admission for confirmed positive covid-19 infections with elevated blood sugar levels as compared to patients who did not receive pioglitazone during their hospitalization for covid-19.


Eligibility criteria:
inclusion criteria: * 18 years or older * laboratory confirmed covid-19 requiring hospitalization * a1c greater than 5.6% as measured in the last 30 days * women of child-bearing potential who agree to use highly effective method of contraception (defined as either abstinence, condom, diaphragm, and/or oral or injected hormonal contraception) during dosing and for 30 days after last dose * mrsa pcr screen negative exclusion criteria: * pregnancy or nursing * congestive heart failure all classes (nyha class i, ii, iii or iv) * liver enzyme alt greater than 2.5 times upper limit of normal * end stage renal disease * hypersensitivity or allergy to a tzd (thiazolidinedione) * active bladder cancer * currently taking a beta blocker, a cyp2c8 inhibitor or inducer such as gemfibrozil or rifampin, a tzd * other current or historical illness that in the opinion of the investigator at attending provider would interfere with the subject's ability to complete the study or make it not in the best interest of the subject to participate

Keywords: covid19 diabetes covid-19 coronavirus